Pientzehuang Pharmaceutical (600436.CH) - The Only "Double Top Secret" Traditional Chinese Medicine
262 Views10 Mar 2021 09:14
The article analyzed Pien Tze Huang in terms of market potential, the scarcity, the impact of price increase, profitability comparison with peers,the moat and insights of Traditional Chinese Medicine.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Oral COVID-19 Antivirals and the Impact on China28 Dec 2021
- Guangzhou Baiyunshan Pharmaceutical Holdings (874.HK) - Conservative About the Outlook23 Dec 2021
- Pientzehuang Pharmaceutical Co., Ltd. (600436.CH) 2021Q3 - Concerns Behind The "Double Top Secret"25 Oct 2021
- Pientzehuang Pharmaceutical (600436.CH) - The Only "Double Top Secret" Traditional Chinese Medicine10 Mar 2021
- Pre-IPO Angelalign Technology - Promising Market but Full of Challenges08 Mar 2021
- New Horizon Health (6606.HK) - Still Has a Long Way to Go04 Mar 2021
- Pre-IPO Chaoju Eye Care Holdings - Here Are the Strength and the Concerns02 Mar 2021
x